THE PMI - Pharma Managers Series – HSE Briefing - Sponsored by AXIS Consulting

  • Thursday, November 5th , 2020
  • Virtual Event
  • 10:00 am – 11:00 am

At the PMI’s meeting on November 5th, Paul Reid, CEO at the HSE will give members an update on the Irish Health Service Executive

Paul Reid, Chief Executive Officer – HSE 

In May 2019 Paul Reid was appointed as Chief Executive Officer of the Health Service Executive where he now leads over 117,000 dedicated staff who deliver a wide range of health services across Ireland. Paul is a passionate public servant whose vision for the health service is to focus on long term planning by implementing Sláintecare and delivering effective and safe services within available resources. He is committed to building confidence and trust in our health service by supporting staff to deliver quality patient care through a new model of integrated services.

Prior to taking up the position of CEO at the HSE , Paul was Chief Executive of Fingal County Council, one of the largest Local Authorities in the state. Under his leadership over the period 2014-2019, Fingal was the leading local authority in terms of social and private housing development. It also led the way in terms of attracting Foreign Direct Investment and job creation across all sectors, through active land management and working with National State Agencies.

Between 2011 and 2014, Paul worked as the Chief Operations Officer in the Department of Public Expenditure & Reform. He was responsible for leading a whole set of reforms across the public service. In this role he negotiated the Haddington Road Agreement, with the 26 Public Service Trade Unions, to reduce the public service pay bill by €1BN.

Paul holds a Masters in Business Administration from Trinity College and a BA in Human Resources and Industrial Relations from the National College Ireland.

As Irelands leading provider of Market Access and Reimbursement submission services, AXIS Consulting is delighted to sponsor the PMI event on Nov 5th at which Paul Reid, CEO of the HSE will give an update on current and future activities within our health service. AXIS will also contribute to the agenda highlighting our recent research findings on reimbursement timelines in Ireland and also speak to some practical considerations to increase the speed at which new innovative medicines reach Irish patients


This event is proudly sponsored by:

Book Now

March 24th 2021 Market Access Masterclass
– Update on the Reimbursement Landscape in Ireland Post Expiration of 2016 IPHA/HSE Framework Agreement

  • Wed, March 24, 2021
  • Mecklenburgh Square, Holborn, London WC1N 2AB, United Kingdom
  • 9:00am – 4:00pm BST

Are you a Market Access Strategist based in the UK company with responsibility for developing submissions to NICE, the SMC and the NCPE? Do you find it challenging to keep up to date with all the challenges in the Irish market access landscape? Would you like to be updated on and understand the changes that will occur once the current extension on the 2016 IPHA HSE framework agreement expires at the end of January 2021?

Don’t miss our Spring 2021 Market Access Masterclass which will be a full-day event, held in Mecklenburgh Square in London on 24th March 2021. Our small round table approach to the event will ensure you leave with all the details and key insights you need to successfully navigate the Irish reimbursement process.

It is our attention at the moment to hold this as a live in-person event, however we will be monitoring the Covid-19 situation closely and will move to an online event should the in-country restrictions and Government guidelines advise

  • Wed, March 24, 2021
  • Mecklenburgh Square, Holborn, London WC1N 2AB, United Kingdom
  • 9:00am – 4:00pm BST
  • In-person event
  • Book Now

Current Events

THE PMI - Pharma Managers Series – HSE Briefing - Sponsored by AXIS Consulting

  • Thursday, November 5th , 2020
  • Virtual Event
  • 10:00 am – 11:00 am

The Value of Medicines Innovation For Society

Medicines innovation creates value for society. New medicines are credited with improving health outcomes. That means people are living longer, healthier lives, with better overall wellbeing and mental health. People are more productive if their health is better so they can contribute to the economy. As well as better treating diseases, medicines are preventing more of them. All this has implications for human capital and for economies – adding healthy life years to populations, boosting productivity and avoiding costs by reducing the burden of disease.

We examine how medicines innovation benefits societies and economies, with a focus on Ireland and Germany. We explore the therapeutic value of medicines in Ireland in areas like cancer and cardiovascular disease, with new insights on how interventions have prolonged life expectancy and kept people active in society. We hear from health and policy and clinical leaders in Germany whose experience with medicines innovation has helped to reset the trajectory of disease. We explain the link between health and opportunity and try to show how medicines innovation is an investment rather than a cost.

We explore all this in partnership with economic research institute and think tank WifOR.

  • October 27, 2020
  • 8am to 9.30am

The Social Determinants of Health

Bold action is needed to rethink how all players in the healthcare ecosystem can work together to treat diseases – and to address their causes. Medicines innovation is adding time and quality to people’s lives. The social determinants of health – often-ignored social factors such as employment, housing, income inequality, and level of access to clean water, education and transport – can undermine progress in raising health outcomes. Governments, in Ireland and around the world, should not ignore these factors.

We examine how social factors can often counteract medical best practice. When health systems implement solutions for people already sick and in crisis, it may be too late. The point of intervention should come before then – and sometimes the best preventative pathways are social rather than therapeutic.

We hear what it takes to build collective will in confronting the social determinants of health. Stakeholders spanning the health ecosystem – policymakers, biopharmaceutical companies, doctors, patients and others – are, in many countries, a loose coalition whose collective focus is often not on creating the social conditions for better health. We ask how that can be improved – for Ireland and for the world.

We explore these themes in partnership with consulting firm PwC.

  • November 5, 2020
  • Virtual Event
  • 8am to 9.30am

Driving A New Future For Healthcare

Data is taking centre stage in the future of global healthcare. No longer passive observers, payers are instead demanding more detailed evidence about the performance of medicines. This shift to a fundamentally patient-centric approach will require the market to adapt to the needs of the ‘empowered consumer’.

So, where is all this leading? What does it mean for healthcare and for medicines development – for patient outcomes and for adoption by health services? The future of healthcare will be driven by radically interoperable data, with open platforms connecting individual, population and environmental datasets in real time. That will allow us to leverage previously untapped or unknown data and arrive at new, revolutionary insights.

We explore these trends in partnership with consulting firm Deloitte.

  • November 12, 2020
  • Virtual Event
  • 8am to 9.30am

#REpharmaEurope - formerly eyeforpharma Barcelona

  • Oct 12, 2021 – Oct 13, 2021
  • Barcelona

Virtual ISPOR Europe 2020

  • 14-18 November 2020
  • Virtual Event

18th & 23rd Sept 2020 Market Access Virtual Masterclass
- Reimbursement in Ireland (Part 1 & 2)

  • September 18th & 23rd, 2020
  • Online Virtual Masterclass
  • Fri, 18 Sep 2020, 09:00am – 12.15pm & Wed, 23 Sep 2020, 09.00am – 12:15pm BST

Do you struggle to understand the Market Access landscape in Ireland? Are you spending valuable time trying to navigate the submission pathway? Would some strategic signposting and ‘on the ground’ local knowledge save you time and money?

Join AXIS CEO Brenda Dooley and her expert team for their Market Access Virtual Masterclass on Reimbursement Applications in Ireland. Normally a one day event, this year’s masterclass will take place online over two half days in September.

The virtual masterclass will provide you with an excellent opportunity to really get behind the scenes of the Irish system, learn how to avoid common submission pitfalls and hear of successful outcomes to reimbursement applications in Ireland.